公开(公告)号：US20180161294A1

公开(公告)日：2018-06-14

申请号：US15891839

申请日：2018-02-08

申请人： Naeem Uddin

发明人： Naeem Uddin

IPC分类号： A61K31/194 ,  A61K9/00 ,  A61P43/00

CPC分类号： A61K31/194 ,  A61K9/0012 ,  A61K9/0095 ,  A61K9/08 ,  A61K9/107 ,  A61K9/14 ,  A61K31/573 ,  A61K2300/00 ,  A61P43/00

摘要： A pharmacological composition for the treatment of bacterial and protozoal infections in a patient. The preferred pharmacological composition comprises a pharmaceutical carrier and an active composition selected from the group consisting of: a) an amount of sodium oxalate and an amount of oxalic acid, b) an amount of sodium citrate and an amount of citric acid, or c) mixtures of a) and b). The amounts and weight ratios of a) the sodium oxalate and oxalic acid, and b) the sodium citrate and citric acid in the active composition are such as to produce a safe and effective pharmacological composition. Sodium salts of other carboxylic acids may be used. The invention also relates to the method of using the pharmacological composition for the safe and effective treatment of bacterial infections, protozoal infections and dermatological diseases.

公开(公告)号：US20160199329A1

公开(公告)日：2016-07-14

申请号：US15062156

申请日：2016-03-06

申请人： Naeem Uddin

发明人： Naeem Uddin

IPC分类号： A61K31/194 ,  A61K8/365 ,  A61K8/362 ,  A61K8/19 ,  A61K31/60 ,  A61K8/368 ,  A61K33/30 ,  A61K8/27 ,  A61K31/573 ,  A61K8/63 ,  A61Q7/00 ,  A61Q3/00 ,  A61Q19/02 ,  A61Q19/00 ,  A61K9/00 ,  A61K9/02 ,  A61K33/00

CPC分类号： A61K31/194 ,  A61K8/19 ,  A61K8/27 ,  A61K8/362 ,  A61K8/365 ,  A61K8/368 ,  A61K8/63 ,  A61K9/0014 ,  A61K9/0019 ,  A61K9/0031 ,  A61K9/0034 ,  A61K9/0053 ,  A61K9/006 ,  A61K9/02 ,  A61K31/56 ,  A61K31/573 ,  A61K31/60 ,  A61K33/00 ,  A61K33/30 ,  A61K33/32 ,  A61K47/00 ,  A61K2800/5922 ,  A61Q3/00 ,  A61Q5/00 ,  A61Q5/02 ,  A61Q7/00 ,  A61Q19/00 ,  A61Q19/02 ,  Y02A50/409 ,  Y02A50/411 ,  Y02A50/414 ,  Y02A50/415 ,  Y02A50/473 ,  Y02A50/475 ,  Y02A50/481 ,  Y02A50/491 ,  A61K2300/00

摘要： A pharmacological composition for the treatment of bacterial and protozoal infections in a patient. The preferred pharmacological composition comprises a pharmaceutical carrier and an active composition selected from the group consisting of: a) an amount of sodium oxalate and an amount of oxalic acid, b) an amount of sodium citrate and an amount of citric acid, or c) mixtures of a) and b). The amounts and weight ratios of a) the sodium oxalate and oxalic acid, and b) the sodium citrate and citric acid in the active composition are such as to produce a safe and effective pharmacological composition. Sodium salts of other carboxylic acids may be used. The invention also relates to the method of using the pharmacological composition for the safe and effective treatment of bacterial infections, protozoal infections and dermatological diseases.

摘要翻译： 用于治疗患者细菌和原生动物感染的药物组合物。 优选的药物组合物包含药物载体和选自以下的活性组合物：a）一定量的草酸钠和一定量的草酸，b）柠檬酸钠的量和柠檬酸的量，或c） a）和b）的混合物。 a）草酸钠和草酸的量和重量比，以及b）活性组合物中的柠檬酸钠和柠檬酸是产生安全有效的药理组合物。 可以使用其它羧酸的钠盐。 本发明还涉及使用药物组合物来安全有效地治疗细菌感染，原生动物感染和皮肤病的方法。

公开(公告)号：US20210346426A1

公开(公告)日：2021-11-11

申请号：US17225053

申请日：2021-04-07

申请人： Naeem Uddin ,  Shamail Zia

发明人： Naeem Uddin ,  Shamail Zia

IPC分类号： A61K33/30 ,  A61K9/00 ,  A61K9/48 ,  A61K33/00 ,  A61K31/194 ,  A61P31/14

摘要： A composition and method for treating COVID 19 by orally administering a pharmacological composition comprising a pharmaceutical carrier and an active composition consisting of about 82% to about 92% Sodium citrate, about 8% to about 18% citric acid and an effective amount of zinc sulfate.

公开(公告)号：US20190137138A1

公开(公告)日：2019-05-09

申请号：US15807594

申请日：2017-11-09

申请人： Naeem Uddin Syed

发明人： Naeem Uddin Syed

IPC分类号： F24F13/08 ,  F24F13/14 ,  F24F11/00

摘要： An eco-friendly register (100) is provided herein. The eco-friendly register (100) includes a grill assembly (102) having a plurality of vents. The eco-friendly register (100) further includes a housing (104) having a butterfly (106), the butterfly (106) having a powered blade (107) and unpowered blade (108) that are rotatable from a first position to a second position to open or close supply of air through the plurality of vents. The eco-friendly register (100) further includes a linkage (120) coupled with the powered blade (107) and the unpowered blade (108), the linkage (120) is configured to slide horizontally from a first wall to a second wall of housing (104), based on rotation of the powered blade (107) from the first position to the second position, the linkage (120) further configured to rotate the unpowered blade (108) from the first position to the second position, based on the sliding. The eco-friendly register (100) further includes a motor (110) configured to rotate the powered blade (107) from the first position to the second position to open or close supply of air through the vents, and a receiver (116) configured to wirelessly receive instructions and control operation of the motor (110) based on the instructions.

公开(公告)号：US09301935B2

公开(公告)日：2016-04-05

申请号：US13913555

申请日：2013-06-10

申请人： Naeem Uddin

发明人： Naeem Uddin

IPC分类号： A61K31/194 ,  A61K31/56 ,  A61K31/573 ,  A61K31/60 ,  A61K33/30 ,  A61K47/00 ,  A61K8/362 ,  A61K8/365 ,  A61Q3/00 ,  A61Q5/00 ,  A61Q5/02 ,  A61Q7/00 ,  A61Q19/00 ,  A61K9/00 ,  A61K9/02 ,  A61K33/32

CPC分类号： A61K31/194 ,  A61K8/19 ,  A61K8/27 ,  A61K8/362 ,  A61K8/365 ,  A61K8/368 ,  A61K8/63 ,  A61K9/0014 ,  A61K9/0019 ,  A61K9/0031 ,  A61K9/0034 ,  A61K9/0053 ,  A61K9/006 ,  A61K9/02 ,  A61K31/56 ,  A61K31/573 ,  A61K31/60 ,  A61K33/00 ,  A61K33/30 ,  A61K33/32 ,  A61K47/00 ,  A61K2800/5922 ,  A61Q3/00 ,  A61Q5/00 ,  A61Q5/02 ,  A61Q7/00 ,  A61Q19/00 ,  A61Q19/02 ,  Y02A50/409 ,  Y02A50/411 ,  Y02A50/414 ,  Y02A50/415 ,  Y02A50/473 ,  Y02A50/475 ,  Y02A50/481 ,  Y02A50/491 ,  A61K2300/00

摘要： The present invention is directed to method of treating a patient suffering from hyperhidrosis by administering a composition comprising a low concentration of sodium oxalate, oxalic acid and hydrocortisone.

摘要翻译： 本发明涉及通过施用包含低浓度草酸钠，草酸和氢化可的松的组合物来治疗患有多汗症的患者的方法。

公开(公告)号：US20210177788A1

公开(公告)日：2021-06-17

申请号：US17178351

申请日：2021-02-18

申请人： Naeem Uddin

发明人： Naeem Uddin

IPC分类号： A61K31/194 ,  A61K31/573 ,  A61K31/192 ,  A61P17/14 ,  A61K47/44 ,  A61K9/00 ,  A61K9/107 ,  A61K31/60 ,  A61P31/04 ,  A61P33/02

摘要： A pharmacological composition for the treatment of bacterial and protozoal infections in a patient. The preferred pharmacological composition comprises a pharmaceutical carrier and an active composition selected from the group consisting of: a)an amount of sodium oxalate and an amount of oxalic acid, b)an amount of sodium citrate and an amount of citric acid, or c)mixtures of a) and b). The amounts and weight ratios of a) the sodium oxalate and oxalic acid, and b) the sodium citrate and citric acid in the active composition are such as to produce a safe and effective pharmacological composition. Sodium salts of other carboxylic acids may be used. The invention also relates to the method of using the pharmacological composition for the safe and effective treatment of bacterial infections, protozoal infections, lice and dermatological diseases.

公开(公告)号：US20200078325A1

公开(公告)日：2020-03-12

申请号：US16688094

申请日：2019-11-19

申请人： Naeem Uddin

发明人： Naeem Uddin

IPC分类号： A61K31/194 ,  A61K31/573 ,  A61K31/192 ,  A61K31/60 ,  A61K47/44 ,  A61K9/00 ,  A61K9/107 ,  A61P17/14

摘要： A pharmacological composition for the treatment of bacterial and protozoal infections in a patient. The preferred pharmacological composition comprises a pharmaceutical carrier and an active composition selected from the group consisting of: a) an amount of sodium oxalate and an amount of oxalic acid, b) an amount of sodium citrate and an amount of citric acid, or c) mixtures of a) and b). The amounts and weight ratios of a) the sodium oxalate and oxalic acid, and b) the sodium citrate and citric acid in the active composition are such as to produce a safe and effective pharmacological composition. Sodium salts of other carboxylic acids may be used. The invention also relates to the method of using the pharmacological composition for the safe and effective treatment of bacterial infections, protozoal infections and dermatological diseases.

公开(公告)号：US09962347B2

公开(公告)日：2018-05-08

申请号：US15062156

申请日：2016-03-06

申请人： Naeem Uddin

发明人： Naeem Uddin

IPC分类号： A61K31/194 ,  A61K31/56 ,  A61K31/573 ,  A61K31/60 ,  A61K33/30 ,  A61K47/00 ,  A61K8/19 ,  A61K8/27 ,  A61K8/368 ,  A61K8/63 ,  A61K9/00 ,  A61K33/00 ,  A61Q19/02 ,  A61K8/362 ,  A61K8/365 ,  A61Q3/00 ,  A61Q5/00 ,  A61Q5/02 ,  A61Q7/00 ,  A61Q19/00 ,  A61K9/02 ,  A61K33/32

CPC分类号： A61K31/194 ,  A61K8/19 ,  A61K8/27 ,  A61K8/362 ,  A61K8/365 ,  A61K8/368 ,  A61K8/63 ,  A61K9/0014 ,  A61K9/0019 ,  A61K9/0031 ,  A61K9/0034 ,  A61K9/0053 ,  A61K9/006 ,  A61K9/02 ,  A61K31/56 ,  A61K31/573 ,  A61K31/60 ,  A61K33/00 ,  A61K33/30 ,  A61K33/32 ,  A61K47/00 ,  A61K2800/5922 ,  A61Q3/00 ,  A61Q5/00 ,  A61Q5/02 ,  A61Q7/00 ,  A61Q19/00 ,  A61Q19/02 ,  Y02A50/409 ,  Y02A50/411 ,  Y02A50/414 ,  Y02A50/415 ,  Y02A50/473 ,  Y02A50/475 ,  Y02A50/481 ,  Y02A50/491 ,  A61K2300/00

摘要： A pharmacological composition for the treatment of bacterial and protozoal infections in a patient. The preferred pharmacological composition comprises a pharmaceutical carrier and an active composition selected from the group consisting of: a) an amount of sodium oxalate and an amount of oxalic acid, b) an amount of sodium citrate and an amount of citric acid, or c) mixtures of a) and b). The amounts and weight ratios of a) the sodium oxalate and oxalic acid, and b) the sodium citrate and citric acid in the active composition are such as to produce a safe and effective pharmacological composition. Sodium salts of other carboxylic acids may be used. The invention also relates to the method of using the pharmacological composition for the safe and effective treatment of bacterial infections, protozoal infections and dermatological diseases.

公开(公告)号：US20140364504A1

公开(公告)日：2014-12-11

申请号：US13913555

申请日：2013-06-10

申请人： Naeem Uddin

发明人： Naeem Uddin

IPC分类号： A61K31/194 ,  A61K31/573 ,  A61K33/30 ,  A61K31/56 ,  A61K47/00 ,  A61K31/60

CPC分类号： A61K31/194 ,  A61K8/19 ,  A61K8/27 ,  A61K8/362 ,  A61K8/365 ,  A61K8/368 ,  A61K8/63 ,  A61K9/0014 ,  A61K9/0019 ,  A61K9/0031 ,  A61K9/0034 ,  A61K9/0053 ,  A61K9/006 ,  A61K9/02 ,  A61K31/56 ,  A61K31/573 ,  A61K31/60 ,  A61K33/00 ,  A61K33/30 ,  A61K33/32 ,  A61K47/00 ,  A61K2800/5922 ,  A61Q3/00 ,  A61Q5/00 ,  A61Q5/02 ,  A61Q7/00 ,  A61Q19/00 ,  A61Q19/02 ,  Y02A50/409 ,  Y02A50/411 ,  Y02A50/414 ,  Y02A50/415 ,  Y02A50/473 ,  Y02A50/475 ,  Y02A50/481 ,  Y02A50/491 ,  A61K2300/00

摘要： A pharmacological composition for the treatment of bacterial and protozoal infections in a patient. The preferred pharmacological composition comprises a pharmaceutical carrier and an active composition selected from the group consisting of a) an amount of sodium oxalate and an amount of oxalic acid, b) an amount of sodium citrate and an amount of citric acid, or c) mixtures of a) and b). The amounts and weight ratios of a) the sodium oxalate and oxalic acid, and b) the sodium citrate and citric acid in the active composition are such as to produce a safe and effective pharmacological composition. Sodium salts of other carboxylic acids may be used. The invention also relates to the method of using the pharmacological composition for the safe and effective treatment of bacterial infections, protozoal infections and dermatological diseases.

摘要翻译： 用于治疗患者细菌和原生动物感染的药物组合物。 优选的药物组合物包含药物载体和选自以下的活性组合物：a）一定量的草酸钠和一定量的草酸，b）柠檬酸钠的量和柠檬酸的量，或c）混合物 的a）和b）。 a）草酸钠和草酸的量和重量比，以及b）活性组合物中的柠檬酸钠和柠檬酸是产生安全有效的药理组合物。 可以使用其它羧酸的钠盐。 本发明还涉及使用药物组合物来安全有效地治疗细菌感染，原生动物感染和皮肤病的方法。

公开(公告)号：US20220008371A1

公开(公告)日：2022-01-13

申请号：US17465894

申请日：2021-09-03

申请人： Naeem Uddin

发明人： Naeem Uddin

IPC分类号： A61K31/194 ,  A61K9/00 ,  A61K31/573 ,  A61P17/08

摘要： A pharmacological composition for the treatment of bacterial and protozoal infections in a patient. The preferred pharmacological composition comprises a pharmaceutical carrier and an active composition selected from the group consisting of: a) an amount of sodium oxalate and an amount of oxalic acid, b) an amount of sodium citrate and an amount of citric acid, or c) mixtures of a) and b). The amounts and weight ratios of a) the sodium oxalate and oxalic acid, and b) the sodium citrate and citric acid in the active composition are such as to produce a safe and effective pharmacological composition. Sodium salts of other carboxylic acids may be used. The invention also relates to the method of using the pharmacological composition for the safe and effective treatment of bacterial infections, protozoal infections, lice and dermatological diseases.